BEND, Ore., Sept. 4, 2024 /PRNewswire/ — In a significant move, CoreRx, Societal CDMO, and Bend Bioscience have announced their unification under the Bend Bioscience brand. This merger brings together three highly respected organizations, each with a unique legacy and distinct strengths, to form a comprehensive contract development and manufacturing organization (CDMO) that offers an end-to-end suite of services.
The decision to adopt the Bend Bioscience name reflects the company’s commitment to innovation, technical excellence and unmatched customer service; a reputation established by Bend Bioscience since its inception. However, this unification equally honors the rich legacies of CoreRx and Societal CDMO, whose contributions and expertise will be foundational to the new brand.
CoreRx has long been recognized for its innovation in formulation development, providing customized, cutting-edge solutions that address some of the most complex challenges in drug development. Their specialized knowledge in the creation of innovative drug delivery systems and complex formulations will continue to be a critical component of Bend Bioscience’s expanded service offerings.
Societal CDMO provides deep expertise in scalable manufacturing and commercial production, with a proven track record of quality and reliability. Their robust capabilities in cGMP manufacturing, packaging, and supply chain management complement the scientific and technical strengths of both CoreRx and Bend Bioscience, allowing the newly combined organization to offer a fully integrated development-to-commercialization pathway for its clients.
“Bend Bioscience was chosen as the unified brand because it encapsulates the scientific excellence and innovative spirit that all three companies represent,” said Owen Murray, CEO of Bend Bioscience. “This merger is not just about combining resources; it’s about building on the strengths of CoreRx’s advanced formulation development, Societal CDMO’s respected manufacturing capabilities in the area of modified release, and Bend Bioscience’s leadership in scientific research and technology. Together, we are creating a CDMO that offers unmatched value and service to our clients and their patients.”
By coming together under the Bend Bioscience brand, the new organization is poised to leverage its combined expertise, enhance operational efficiencies, and deliver comprehensive, high-quality services that help bring life-saving therapies to market faster and more efficiently.
About Bend Bioscience
Bend Bioscience is a premier CDMO formed from the unification of CoreRx, Societal CDMO, and Bend Bioscience, providing innovative solutions for every phase of drug development and manufacturing. With a commitment to quality, science, and service, Bend Bioscience operates state-of-the-art facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia, enabling it to serve clients globally with comprehensive and integrated capabilities across multiple locations. Our goal is to partner with clients to turn complex molecules into meaningful medicines. Learn more at www.bendbioscience.com
For media inquiries, please contact:
Melissa Sullivan
Director of Marketing + Communications
Bend Bioscience
Email: media@bendbioscience.com
SOURCE Bend Bioscience
Sends Letter to Shareholders Reiterating Why Voting for Both Politan’s “Highly Credible and Capable” Nominees…
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…
WESTON, Mass., Sept. 6, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative…
TEMPE, Ariz., Sept. 6, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in August…
NAHQ next brings together 150 leading experts to present innovative ideas and solutions in healthcare…
Strategic collaboration strengthens end-to-end connectivity & data flow across the drug development platform, ensuring seamless…